News | Proton Therapy | September 17, 2019

IBA Gathers Experts on Flash Irradiation During ASTRO

Key opinion leaders in the field of proton therapy shared their latest insights and research on Flash irradiation during IBA’s 3rd Victoria Consortium Meeting and IBA’s symposium on proton therapy

IBA Gathers Experts on Flash Irradiation During ASTRO

September 17, 2019 — IBA (Ion Beam Applications SA, held its third Victoria Consortium Meeting focusing on Flash irradiation at the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago.

In addition, during IBA’s annual symposium on proton therapy, Amit Maity, M.D., executive vice-chair radiation oncology, Perelman School of Medicine, University of Pennsylvania, also shared the latest insight on proton Flash radiation therapy for gastrointestinal (GI) malignancies.  

Flash therapy has the potential to dramatically change the landscape of radiotherapy and patient cancer care, making it more effective and more accessible than conventional radiotherapy. Flash irradiation is a fast and powerful treatment that delivers a high dose of radiation at an ultra-high dose rate. This novel technique could potentially shorten treatment time from 6-8 weeks to less than a week, and has the potential to reduce side effects for patients.

IBA is collaborating with several leading proton therapy centers in their research work to better understand the mechanisms of Flash irradiation. This early development work enables IBA today to deliver Flash irradiation on both its current single- and multi-room proton therapy platforms in a clinical environment in research mode, as demonstrated in March 2019 at the University Medical Center of Groningen, The Netherlands, and in June 2019 at the Rutherford Cancer Center Thames Valley in Reading, England. 

Alexander Lin, M.D., associate professor of radiation oncology and chief of the Head and Neck Oncology Service at the Hospital of the University of Pennsylvania, Philadelphia, commented, “Flash is a very exciting opportunity and we believe that proton therapy can be a very suitable modality to achieve the desired outcomes. We are at a stage where more research is needed to better understand the mechanisms of FLASH irradiation, and we are very excited about our current research program at Penn Medicine. Coordinating our efforts with other centers is key, and IBA’s Victoria meeting offered a great forum to share our insights.”

Flash therapy is currently under research and is not available for sale.

For more information: www.iba-worldwide.com

Related Content

Newly released study results present a strong case for lung cancer screening in New Zealand — particularly for Māori whose mortality rates are between three and four times higher than other ethnic groups.

Image courtesy of Siemens Healthineers

News | Lung Imaging | September 30, 2020
September 30, 2020 — Newly released study results present a strong case for...
he Centers for Medicare and Medicaid Services (CMS) published the “Specialty Care Models to Improve Quality of Care and Reduce Expenditures (CMS-5527)” final rule.

Getty Images

News | Radiation Oncology | September 29, 2020
September 29, 2020 — On Sept.
Important milestone demonstrates the unrivalled experience, technological innovation and global market leadership of IBA and its clinical partners
News | Proton Therapy | September 25, 2020
September 25, 2020 — IBA (Ion Beam Applications SA) announced that more than 100,000 patients have now been treated w
Philips Azurion Lung Edition supports high precision diagnosis and minimally invasive therapy in one room
News | Lung Imaging | September 21, 2020
September 21, 2020 — Philips introduced...
Final rule includes mandatory participation for nearly 1,000 practices and does not allow sufficient time for transition

Getty Images

News | Radiation Oncology | September 21, 2020
September 21, 2020 — In response to the September 18 ...
According to a new report published by P&S Intelligence, the global radiotherapy market is expected to expand from $7.2M in 2019 to $17M by 2030.

Image courtesy of Accuray

Feature | Radiation Therapy | September 21, 2020 | By Melinda Taschetta-Millane
According to a...
Breast cancer patients whose disease has spread to their brains fare better if their metastases are picked up before they begin to cause symptoms, according to a study presented at the 12th European Breast Cancer Conference.

Getty Images

News | Breast Imaging | September 21, 2020
September 21, 2020 — Breast cancer patients whose disease has spread to their brains fare better if their metastases
Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s